By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), a clinical-stage biopharmaceutical company, announced it signed an agreement with global pharmaceutical and biotech partner Lonza. The collaboration includes the manufacturing of sabirnetug (ACU193), an antibody for the treatment of Alzheimer’s disease...

By Daniella Parra Gameto, a biotech firm focused on women’s healthcare, shared a study examining the impact of minimal controlled ovarian stimulation on egg retrieval experiences. The analysis involved 110 patients with minimal stimulation cycles followed by OSC-IVM, 48 patients...

By Karen Roman REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, said its subretinal treatment of age-related macular degeneration showed improved vision in patients. Two years of data were published in The Lancet regarding the ongoing trials of ABBV-RGX-314, its...

By Karen Roman Agendia, Inc., a biotechnology company that provides molecular diagnostics and cancer treatment, said it can predict response and nonresponse to common neoadjuvant immunotherapy for patients with triple negative breast cancer. Agendia holds an FDA Investigational Device Exempt...

By Daniella Parra Conduit Pharmaceuticals Inc. (Nasdaq: CDT) announced the appointment of Dr. Joanne Holland as Chief Scientific Officer and Dr. Jeff Lindeman as a Consultant on intellectual property strategies. The company said Dr. Holland brings over 20 years of...

By Karen Roman Conduit Pharmaceuticals Inc. (Nasdaq: CDT), a clinical-stage life science company, reported it has opened a new cutting-edge laboratory space in Cambridge, U.K. This new facility sits within a space of 150 acres and 2 million square feet...

By Daniella Parra Promontory Therapeutics Inc. completed enrollment of 109 late-stage metastatic castration-resistant prostate cancer patients for its Phase 2 trial of PT-112, which assesses its efficacy in patients who have undergone prior treatments, the company said. PT-112 is a...

By Daniella Parra Sparrow Pharmaceuticals continues its PROST! Phase 2 clinical trial for treating polymyalgia rheumatica (PMR) with SPI-62 and prednisolone, adding a fourth cohort, they said. PMR, an autoimmune disorder common among the elderly, traditionally treated with steroids like...

By Karen E. Roman Apollomics, Inc. (Nasdaq: APLM), a biopharmaceutical company that develops medicines for difficult-to-treat cancers, said it appointed Matthew Plunkett, Ph.D., as Chief Financial Officer. Dr. Plunkett has over 25 years of strategic and financial experience within the...

By Exec Edge Editorial Staff RBC Capital analyst Shagun Singh maintained Zynex, Inc. (Nasdaq:ZYXI) with an outperform rating and raised its price target from $13 to $15. Meanwhile, HC Wainwright & Co. analyst Yi Chen maintained a buy rating and...